MiR-21 down-regulation suppresses cell growth, invasion and induces cell apoptosis by targeting FASL, TIMP3, and RECK genes in esophageal carcinoma

Digestive Diseases and Sciences

Volumn 58, Issue 7, 2013, Pages 1863-1870

  Wang, Na ^a   Zhang, Chao Qi ^a   He, Jia Huan ^a   Duan, Xiao Fei ^a   Wang, Yuan Yuan ^a   Ji, Xiang ^a   Zang, Wen Qiao ^a   Li, Min ^a   Ma, Yun Yun ^a   Wang, Tao ^b   Zhao, Guo Qiang ^a  

^a ZHENGZHOU UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF HENAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Esophageal neoplasms; Fas ligand; miR 21; RECK; Tissue inhibitor of metalloproteinase 3

Indexed keywords

FAS LIGAND; LUCIFERASE; MICRORNA 21; PROTEIN DERIVATIVE; RECK PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 3; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL GROWTH; CELL INVASION; CLINICAL ARTICLE; DOWN REGULATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; ESOPHAGEAL NEOPLASMS; FAS LIGAND PROTEIN; FEMALE; GPI-LINKED PROTEINS; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM INVASIVENESS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84879842127     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-013-2612-2     Document Type: Article

References (36)

1. Hongo M, Nagasaki Y, Shoji T. Epidemiology of esophageal cancer: Orient to Occident. Effects of chronology, geography and ethnicity. J Gastroenterol Hepatol. 2009;24:729-735.
2. Dawsey SP, Tonui S, Parker RK, et al. Esophageal cancer in young people: a case series of 109 cases and review of the literature. PLoS ONE. 2010;5:e14080.
3. D'Journo XB, Michelet P, Dahan L, et al. Indications and outcome of salvage surgery for oesophageal cancer. Eur J Cardiothorac Surg. 2008;33:1117-1123.
4. Baxi SH, Burmeister B, Harvey JA, et al. Salvage definitive chemo-radiotherapy for locally recurrent oesophageal carcinoma after primary surgery: retrospective review. J Med Imaging Radiat Oncol. 2008;52:583-587.
5. Matsushima K, Isomoto H, Kohno S, et al. MicroRNAs and esophageal squamous cell carcinoma. Digestion. 2010;82:138-144.
6. Kimura S, Naganuma S, Susuki D, et al. Expression of microRNAs in squamous cell carcinoma of human head and neck and the esophagus: miR-205 and miR-21 are specific markers for HNSCC and ESCC. Oncol Rep. 2010;23:1625-1633.
7. Toh Y, Oki E, Ohgaki K, et al. Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: molecular mechanisms of carcinogenesis. Int J Clin Oncol. 2010;15:135-144.
8. Osman A. MicroRNAs in health and disease - basic science and clinical applications. Clin Lab. 2012;58:393-402.
9. Wang Y, Lee CG. MicroRNA and cancer - focus on apoptosis. J Cell Mol Med. 2009;13:12-23.
10. Li S, Liang Z, Xu L, et al. MicroRNA-21: a ubiquitously expressed pro-survival factor in cancer and other diseases. Mol Cell Biochem. 2012;360:147-158.
11. Zhao L, Chen X, Cao Y. New role of microRNA: carcinogenesis and clinical application in cancer. Acta Biochim Biophys Sin (Shanghai). 2011;43:831-839.
12. Liu J, Zheng M, Tang YL, et al. MicroRNAs, an active and versatile group in cancers. Int J Oral Sci. 2011;3:165-175.
13. Hermeking H. MicroRNAs in the p53 network: micromanagement of tumour suppression. Nat Rev Cancer. 2012;12:613-626.
14. He B, Yin B, Wang B, et al. MicroRNAs in esophageal cancer (review). Mol Med Rep. 2012;6:459-465.
15. Feber A, Xi L, Pennathur A, et al. MicroRNA prognostic signature for nodal metastases and survival in esophageal adenocarcinoma. Ann Thorac Surg. 2011;91:1523-1530.
16. Gao W, Xu J, Liu L, et al. A systematic-analysis of predicted miR-21 targets identifies a signature for lung cancer. Biomed Pharmacother. 2012;66:21-28.
17. Schee K, Boye K, Abrahamsen TW, et al. Clinical relevance of microRNA mir-21, mir-31, mir-92a, mir-101, mir-106a and mir-145 in colorectal cancer. BMC Cancer. 2012;12:505.
18. Feber A, Xi L, Luketich JD, et al. MicroRNA expression profiles of esophageal cancer. J Thorac Cardiovasc Surg. 2008;135:255-260.
19. Mori Y, Ishiguro H, Kuwabara Y, et al. MicroRNA-21 induces cell proliferation and invasion in esophageal squamous cell carcinoma. Mol Med Rep. 2009;2:235-239.
20. Mathé EA, Nguyen GH, Bowman ED, et al. MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res. 2009;15:6192-6200.
21. Ma WJ, Lv GD, Tuersun A, et al. Role of microRNA-21 and effect on PTEN in Kazakh's esophageal squamous cell carcinoma. Mol Biol Rep. 2011;38:3253-3260.
22. Sayed D, He M, Hong C, et al. MicroRNA-21 is a downstream effector of AKT that mediates its antiapoptotic effects via suppression of Fas ligand. J Biol Chem. 2010;285:20281-20290.
23. Nagao Y, Hisaoka M, Matsuyama A, et al. Association of microRNA-21 expression with its targets, PDCD4 and TIMP3, in pancreatic ductal adenocarcinoma. Mod Pathol. 2012;25:112-121.
24. Zibert JR, Løvendorf MB, Litman T, et al. MicroRNAs and potential target interactions in psoriasis. J Dermatol Sci. 2010;58:177-185.
25. Reis ST, Pontes-Junior J, Antunes AA, et al. miR-21 may acts as an oncomir by targeting RECK, a matrix metalloproteinase regulator, in prostate cancer. BMC Urol. 2012;12:14.
26. Rabien A, Ergün B, Erbersdobler A, et al. RECK overexpression decreases invasive potential in prostate cancer cells. Prostate. 2012;72:948-954.
27. Han L, Yue X, Zhou X, et al. MicroRNA-21 expression is regulated by β-catenin/STAT3 pathway and promotes glioma cell invasion by direct targeting RECK. CNS Neurosci Ther. 2012;18:573-583.
28. Gaur AB, Holbeck SL, Colburn NH, et al. Downregulation of Pdcd4 by mir-21 facilitates glioblastoma proliferation in vivo. Neuro Oncol. 2011;13:580-590.
29. Lee JA, Lee HY, Lee ES, et al. Prognostic implications of microRNA-21 overexpression in invasive ductal carcinomas of the breast. J Breast Cancer. 2011;14:269-275.
30. Zhong Z, Dong Z, Yang L, et al. miR-21 induces cell cycle at S phase and modulates cell proliferation by down-regulating hMSH2 in lung cancer. J Cancer Res Clin Oncol. 2012;138:1781-1788.
31. Buscaglia LE, Li Y. Apoptosis and the target genes of microRNA-21. Chin J Cancer. 2011;30:371-380.
32. Zhu S, Wu H, Wu F, et al. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res. 2008;18:350-359.
33. Pan X, Wang ZX, Wang R. MicroRNA-21: a novel therapeutic target in human cancer. Cancer Biol Ther. 2011;10:1224-1232.
34. Xue LY, Ren LQ, Luo W, et al. Expression of Fas, Fas ligand, Fas-associated death domain protein, caspase 8 and mutant P53 protein in esophageal squamous cell carcinoma. Zhonghua Yi Xue Za Zhi. 2007;87:150-154 (article in Chinese).
35. Ninomiya I, Kawakami K, Fushida S, et al. Quantitative detection of TIMP-3 promoter hypermethylation and its prognostic significance in esophageal squamous cell carcinoma. Oncol Rep. 2008;20:1489-1495.
36. Li SL, Gao DL, Zhao ZH, et al. Correlation of matrix metalloproteinase suppressor genes RECK, VEGF, and CD105 with angiogenesis and biological behavior in esophageal squamous cell carcinoma. World J Gastroenterol. 2007;13:6076-6081.